60 Degrees Pharmaceuticals Inc. Common Stock (SXTP)

FairStock Score: 34/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I am wary when a $3.2M market-cap company trades at $0.90, as of the 2026-10-13 close, and loses money. 60 Degrees Pharmaceuticals has an approved malaria-prevention product, Arakoda, and early-stage Tafenoquine programs in COVID-19, babesiosis, fungal and pneumocystis pneumonia. That is a lottery-ticket pipeline, not a moat. In fiscal Q2 2026, the quarter ended 2026-06-30, filed revenue was $207,898 and net loss was $2.3M. In fiscal Q2 2025, the quarter ended 2025-06-30, revenue was $100,932 and net loss was $1.7M. Revenue grew, but losses expanded. For FY2025, revenue was $1.0M and net loss was $7.4M; FY2024 revenue was $607,574 and net loss was $7.9M. The business has not earned a profit in the last four years, so the Lynch category is none. FairStock calculations show P/E -0.34, ROE -332.85%, ROCE -127.11%, FCF -$9.1M TTM, FCF yield -286.3%, Piotroski 2/9, Altman Z -17.10. The only balance-sheet comfort is D/E 0.06 and a tiny employee base. But with cash burn far exceeding market cap, equity holders are likely to be diluted or left with little if trials fail. FairStock Score 34/100 and beta 2.54 confirm high risk. The price may look statistically cheap because sales and assets are small, but Graham would demand a margin of safety that these numbers do not provide. I see a speculative biotech, not a value investment.

In plain English: 60 Degrees Pharmaceuticals is a very small healthcare company with an approved malaria-prevention medicine and several experimental treatments. The business is not profitable, sales are tiny, and it is burning cash, so it looks financially weak. At $0.90 per share, the stock looks very cheap compared with sales, but cheap can be misleading when losses and cash needs are large.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer